Maternal Child Health Bureau, Healthy Start Eliminating Disparities in Perinatal Health, 27153-27154 [E9-13279]
Download as PDF
<![CDATA[
cprice-sewell on PRODPC61 with NOTICES
Federal Register / Vol. 74, No. 108 / Monday, June 8, 2009 / Notices
as mandated by FDAAA, the provisions
of the proposed rule went into effect on
that date.
FDAAA mandated one change to the
proposed rule. Section 502(f)(2) of
FDAAA stated that the toll-free number
proposed rule shall not apply to overthe-counter (OTC) drugs marketed with
an application approved under section
505 of the act (application OTC drug
products) if these application OTC drug
products meet certain labeling
requirements. Because the agency’s
rulemaking process was ongoing on
January 1, 2008, an interim final rule
was issued on January 3, 2008 (73 FR
402) that codified the provisions of the
proposed rule as modified by FDAAA.
The interim final rule stated that FDA
anticipated that affected entities would
need time to update labeling and
systems to comply with the new
requirements and that FDA intended to
exercise its enforcement discretion and
not take action to enforce the toll-free
number requirements in the interim
final rule until January 1, 2009. The
interim final rule also stated that the
agency planned to complete research
begun on the proposed labeling
statements and would issue a final rule
taking into account the results of that
research. In the Federal Register of
October 28, 2008 (73 FR 63886), FDA
issued a final rule with an effective date
of November 28, 2008, and a
compliance date of July 1, 2009. The
agency is publishing this guidance to
assist manufacturers in complying with
the final rule.
This level 1 guidance is being issued
for immediate implementation
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
FDA has determined that prior public
participation is not feasible or
appropriate because the side effects
statement is required by Congress and
the compliance deadline for its
inclusion in Medication Guides is July
1, 2009 (21 CFR 10.115(g)(2)). If
comments are received on this level 1
guidance, FDA will review the
comments and revise the guidance if
appropriate. The guidance represents
the agency’s current thinking on adding
a toll-free number to Medication Guides
and reporting this to the agency. It does
not create or confer any rights for or on
any person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statutes and regulations.
II. The Paperwork Reduction Act of
1995
The required side effects statement is
not subject to the Office of Management
VerDate Nov<24>2008
15:15 Jun 05, 2009
Jkt 217001
and Budget (OMB) review under the
Paperwork Reduction Act (PRA) (44
U.S.C. 3501–3520) because it is
‘‘originally supplied by the Federal
Government to the recipient for the
purpose of disclosure to the public’’ and
is not considered a collection of
information under the PRA (5 CFR
1320.3(c)(2)). The guidance on notifying
FDA in the drug’s annual report that the
side effects statement has been added to
the drug’s Medication Guide is covered
by previously approved collections of
information found in FDA regulations.
The collections of information in 21
CFR 314.70(d) (changes to an approved
application to be described in an annual
report) and 314.81(b)(2)(iii)(c) (a
summary of labeling changes that have
been made since the last annual report)
have been approved under OMB control
number 0910–0001 for human drugs.
III. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
IV. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
Dated: June 1, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–13273 Filed 6–5–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Maternal Child Health Bureau, Healthy
Start Eliminating Disparities in
Perinatal Health
AGENCY: Health Resources and Services
Administration (HRSA), U.S.
Department of Health and Human
Services.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
27153
ACTION: Notice of Non-competitive
Supplemental Funding to Northern
Manhattan Perinatal Partnership.
SUMMARY: The Health Resources and
Services Administration (HRSA) is
issuing non-competitive supplemental
funding under the Maternal Child
Health Bureau, Healthy Start
Eliminating Disparities in Perinatal
Health program to ensure that the
Northern Manhattan Perinatal
Partnership (NMPP), the primary
provider of prenatal services in Central
Harlem, can continue to provide much
needed services to help stem the rise in
and ultimately reduce the Infant
Mortality Rate (IMR) in the affected
service area.
SUPPLEMENTARY INFORMATION:
Intended Recipient of the Award:
Northern Manhattan Perinatal
Partnership.
Amount of the Non-Competitive
Supplemental Funding: $510, 417.
Project Period: The original project
period for this grant is through May 31,
2009.
Period of Supplemental Support: June
1, 2009 through January 31, 2010.
Authority: This activity is under the
authority of the Public Health Service
Act, Section 33OH.
Catalogue of Federal Domestic
Assistance Number: 93.926.
Justication for Non-Competitive
Supplemental Funding
Northern Manhattan Perinatal
Partnership (NMPP), known as Central
Harlem Healthy Start, has historically
been the primary provider of prenatal
services in Central Harlem and has been
highly effective in reducing the high
rate of infant morality (IMR) in that
project/service area. As a consequence
of NMPP’s leadership and collaborated
efforts with other providers in the
community, the IMR has declined
significantly in Central Harlem since the
initiation of the project in 1990 when it
was 27.7 infant deaths per 1,000 live
births. By 2001, the IMR had dropped to
13.1 infant deaths per 1,000 live births,
54% less than the 1990 rate. The IMR
in Central Harlem from 2002 to 2004
showed a decline from the previous
years; however, there were fluctuations
in the rate of decline in the community.
The IMR was at a low of 6.2% in 2002
and increased to 7.3% in 2003, and then
in 2004, decreased to 5.1%. The
apparent trend in the following two
years saw a steady increase to 7.4% for
2005 and 11.2% for 2006. An additional
indicator of this trend is the escalating
IMR for teen births which saw an
increase in the 3 year average from
E:\FR\FM\08JNN1.SGM
08JNN1
27154
Federal Register / Vol. 74, No. 108 / Monday, June 8, 2009 / Notices
2002–2004 of 5.93% increase to 12.54%
for 2005–2007.
The reduction in the earlier years IMR
(2002–2004) for Central Harlem made
them ineligible for the FY 2009 Healthy
Start Eliminating Disparities Open
competition. To be eligible, the IMR for
the service area had to be 1.5 times the
national average for the period of 2002–
2004 or 10.35. In FY 2010 there will be
another Healthy Start Eliminating
Disparities Open competition and
grantees will be required to the use the
most recently available IMR data (2004–
2006 or 2005–2007) to compete. To be
eligible for the competition, grantees
will have to have an IMR that is 1.5
times the national average for the
project area for either 2004–2006 or
2005–2007. Data supplied the New York
City Bureau Statistics indicates that
Central Harlem would be eligible for
this competition because they have
12.54% IMR for teen births for 2005–
2007.
The award of non-competitive
supplemental funding will enable
NMPP to provide much need services in
Central Harlem. Given the current
economic situation and the rising IMR
rate in the project area, the loss of this
experienced provider of health services
would be devastating and would
contribute to the rise in infant deaths in
Central Harlem, NMPP is the primary
provider of comprehensive communitybased perinatal services and the only
Healthy Start site serving the project
area. The project’s dedication and
commitment to the residents of Harlem
since 1999 could not be replaced
another community based provider.
FOR FURTHER INFORMATION CONTACT: John
McGovern, Public Health Analyst,
Division of Healthy Start and Perinatal
Services, Maternal and Child Health
Bureau, HRSA, Room 18–12, Parklawn
Building, 5600 Fishers Lane, Rockville,
MD 20857; phone 301–443–5805; E-mail
jmcgovern@hrsa.gov.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel Competitive Revision—ARRA Funds.
Date: June 11, 2009.
Time: 1:45 p.m. to 3:45 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Room 3AN18, 45 Center
Drive, Bethesda, MD 20892. (Telephone
Conference Call).
Contact Person: Rebecca H Johnson, PhD,
Scientific Review Administrator, Office of
Scientific Review, National Institute of
General Medical Sciences, National Institutes
of Health, Natcher Building, Room 3AN18C,
Bethesda, MD 20892. 301–594–2771.
johnsonrh@nigms.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.701, ARRA
Related Biomedical Research and Research
Support Awards, National Institutes of
Health, HHS)
Dated: June 1, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–13199 Filed 6–5–09; 8:45 am]
BILLING CODE 4140–01–M
Dated: May 29, 2009.
Mary K. Wakefield,
Administrator.
[FR Doc. E9–13279 Filed 6–5–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4165–15–P
National Institutes of Health
National Institutes of Health
cprice-sewell on PRODPC61 with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
VerDate Nov<24>2008
15:15 Jun 05, 2009
Jkt 217001
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel—Program Project.
Date: July 10, 2009.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: NIH, Democracy II, 6701 Democracy
Plaza II, 200, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: John K. Hayes, PhD,
Scientific Review Officer, 6707 Democracy
Boulevard, Suite 959, Bethesda, MD 20892,
301–451–3398, hayesj@mail.nih.gov.
Dated: June 1, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–13282 Filed 6–5–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel. Animal Models of Infectious
Diseases 1.
Date: June 29–July 1, 2009.
Time: 8 a.m. to 7 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Crowne Plaza—Silver Spring, 8777
Georgia Avenue, Silver Spring, MD 20910.
Contact Person: Tracy A. Shahan, PhD,
MBA, Scientific Review Officer, Scientific
Review Program, NIH/NIAID/DHHS, Room
3121, 6700B Rockledge Drive, MSC 7616,
E:\FR\FM\08JNN1.SGM
08JNN1
]]>Agencies
[Federal Register Volume 74, Number 108 (Monday, June 8, 2009)]
[Notices]
[Pages 27153-27154]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-13279]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Maternal Child Health Bureau, Healthy Start Eliminating
Disparities in Perinatal Health
AGENCY: Health Resources and Services Administration (HRSA), U.S.
Department of Health and Human Services.
ACTION: Notice of Non-competitive Supplemental Funding to Northern
Manhattan Perinatal Partnership.
-----------------------------------------------------------------------
SUMMARY: The Health Resources and Services Administration (HRSA) is
issuing non-competitive supplemental funding under the Maternal Child
Health Bureau, Healthy Start Eliminating Disparities in Perinatal
Health program to ensure that the Northern Manhattan Perinatal
Partnership (NMPP), the primary provider of prenatal services in
Central Harlem, can continue to provide much needed services to help
stem the rise in and ultimately reduce the Infant Mortality Rate (IMR)
in the affected service area.
SUPPLEMENTARY INFORMATION:
Intended Recipient of the Award: Northern Manhattan Perinatal
Partnership.
Amount of the Non-Competitive Supplemental Funding: $510, 417.
Project Period: The original project period for this grant is
through May 31, 2009.
Period of Supplemental Support: June 1, 2009 through January 31,
2010.
Authority: This activity is under the authority of the Public
Health Service Act, Section 33OH.
Catalogue of Federal Domestic Assistance Number: 93.926.
Justication for Non-Competitive Supplemental Funding
Northern Manhattan Perinatal Partnership (NMPP), known as Central
Harlem Healthy Start, has historically been the primary provider of
prenatal services in Central Harlem and has been highly effective in
reducing the high rate of infant morality (IMR) in that project/service
area. As a consequence of NMPP's leadership and collaborated efforts
with other providers in the community, the IMR has declined
significantly in Central Harlem since the initiation of the project in
1990 when it was 27.7 infant deaths per 1,000 live births. By 2001, the
IMR had dropped to 13.1 infant deaths per 1,000 live births, 54% less
than the 1990 rate. The IMR in Central Harlem from 2002 to 2004 showed
a decline from the previous years; however, there were fluctuations in
the rate of decline in the community. The IMR was at a low of 6.2% in
2002 and increased to 7.3% in 2003, and then in 2004, decreased to
5.1%. The apparent trend in the following two years saw a steady
increase to 7.4% for 2005 and 11.2% for 2006. An additional indicator
of this trend is the escalating IMR for teen births which saw an
increase in the 3 year average from
[[Page 27154]]
2002-2004 of 5.93% increase to 12.54% for 2005-2007.
The reduction in the earlier years IMR (2002-2004) for Central
Harlem made them ineligible for the FY 2009 Healthy Start Eliminating
Disparities Open competition. To be eligible, the IMR for the service
area had to be 1.5 times the national average for the period of 2002-
2004 or 10.35. In FY 2010 there will be another Healthy Start
Eliminating Disparities Open competition and grantees will be required
to the use the most recently available IMR data (2004-2006 or 2005-
2007) to compete. To be eligible for the competition, grantees will
have to have an IMR that is 1.5 times the national average for the
project area for either 2004-2006 or 2005-2007. Data supplied the New
York City Bureau Statistics indicates that Central Harlem would be
eligible for this competition because they have 12.54% IMR for teen
births for 2005-2007.
The award of non-competitive supplemental funding will enable NMPP
to provide much need services in Central Harlem. Given the current
economic situation and the rising IMR rate in the project area, the
loss of this experienced provider of health services would be
devastating and would contribute to the rise in infant deaths in
Central Harlem, NMPP is the primary provider of comprehensive
community-based perinatal services and the only Healthy Start site
serving the project area. The project's dedication and commitment to
the residents of Harlem since 1999 could not be replaced another
community based provider.
FOR FURTHER INFORMATION CONTACT: John McGovern, Public Health Analyst,
Division of Healthy Start and Perinatal Services, Maternal and Child
Health Bureau, HRSA, Room 18-12, Parklawn Building, 5600 Fishers Lane,
Rockville, MD 20857; phone 301-443-5805; E-mail jmcgovern@hrsa.gov.
Dated: May 29, 2009.
Mary K. Wakefield,
Administrator.
[FR Doc. E9-13279 Filed 6-5-09; 8:45 am]
BILLING CODE 4165-15-P
